

# Luchino Chessa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6928669/publications.pdf>

Version: 2024-02-01

54  
papers

1,303  
citations

516215

16  
h-index

360668

35  
g-index

56  
all docs

56  
docs citations

56  
times ranked

1955  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term benefit of interferon $\alpha$ therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. <i>Gastroenterology</i> , 2004, 126, 1740-1749.	0.6	288
2	Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 3081-3086.	3.3	195
3	Randomised study comparing 48 and 96 weeks peginterferon $\alpha$ -2a therapy in genotype D HBeAg-negative chronic hepatitis B. <i>Gut</i> , 2013, 62, 290-298.	6.1	105
4	Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience. <i>Frontiers in Immunology</i> , 2020, 11, 605688.	2.2	92
5	Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2007, 3, 22.	0.6	72
6	Association of chronic hepatitis C with recurrent brief depression. <i>Journal of Affective Disorders</i> , 2012, 141, 361-366.	2.0	48
7	Treatment of chronic hepatitis D. <i>Journal of Viral Hepatitis</i> , 2007, 14, 58-63.	1.0	42
8	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , 2017, 12, e0185728.	1.1	37
9	Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection. <i>PLoS ONE</i> , 2021, 16, e0255608.	1.1	34
10	Forecasting Hepatitis C liver disease burden on real-life data. Does the <i>hidden iceberg</i> matter to reach the elimination goals?. <i>Liver International</i> , 2018, 38, 2190-2198.	1.9	33
11	Real-world experience with obeticholic acid in patients with primary biliary cholangitis. <i>JHEP Reports</i> , 2021, 3, 100248.	2.6	33
12	Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis. <i>PLoS ONE</i> , 2016, 11, e0146086.	1.1	26
13	Gastrointestinal coronavirus disease 2019: epidemiology, clinical features, pathogenesis, prevention, and management. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 41-50.	1.4	26
14	Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. <i>Hepatology</i> , 2017, 66, 1814-1825.	3.6	25
15	Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. <i>Journal of Hepatology</i> , 2018, 68, 33-41.	1.8	19
16	Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination. <i>Clinical and Experimental Medicine</i> , 2022, 22, 477-485.	1.9	18
17	Hepatitis C in the elderly: A multicentre cross-sectional study by the Italian Association for the Study of the Liver. <i>Digestive and Liver Disease</i> , 2012, 44, 674-680.	0.4	17
18	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	3.7	15

#	ARTICLE	IF	CITATIONS
19	Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology. <i>Journal of Hepatology</i> , 2021, 75, 1355-1366.	1.8	15
20	Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. <i>Tumori</i> , 2018, 104, 476-479.	0.6	14
21	A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. <i>Hepatology</i> , 2022, 76, 220-232.	3.6	12
22	Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1274-1282.	0.6	11
23	Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin. <i>Haematologica</i> , 2006, 91, ECR26.	1.7	10
24	Evaluation of humoral and cellular response to third dose of BNT162b2 mRNA COVID-19 vaccine in patients treated with B-cell depleting therapy. <i>Journal of Autoimmunity</i> , 2022, 131, 102848.	3.0	10
25	Absence of activating killer immunoglobulin-like receptor genes combined with hepatitis C viral genotype is predictive of hepatocellular carcinoma. <i>Human Immunology</i> , 2013, 74, 1288-1294.	1.2	9
26	Previous Functional Social and Behavioral Rhythms Affect Resilience to Covid-19-Related Stress among Old Adults. <i>Journal of Public Health Research</i> , 2022, 11, jphr.2022.2768.	0.5	9
27	Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. <i>Hepatology International</i> , 2020, 14, 362-372.	1.9	8
28	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. <i>Infection</i> , 2018, 46, 607-615.	2.3	7
29	Entropy of human leukocyte antigen and killer-cell immunoglobulin-like receptor systems in immune-mediated disorders: A pilot study on multiple sclerosis. <i>PLoS ONE</i> , 2019, 14, e0226615.	1.1	6
30	Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. <i>Digestive and Liver Disease</i> , 2021, 53, 612-619.	0.4	6
31	Review article: safety of new biologic agents for inflammatory bowel disease in the liver. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 623-630.	0.8	5
32	The Covid-19 Incidence in Italian Regions Correlates with Low Temperature, Mobility and Pm10 Pollution but Lethality Only with Low Temperature. <i>Journal of Public Health Research</i> , 2021, 10, jphr.2021.2303.	0.5	5
33	Neutralizing Antibodies Responses against SARS-CoV-2 in a Sardinian Cohort Group Up to 9 Months after BNT162b2 Vaccination. <i>Vaccines</i> , 2022, 10, 531.	2.1	5
34	Evaluation of Antibody Response to Heterologous Prime-Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study. <i>Vaccines</i> , 2021, 9, 1478.	2.1	5
35	Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful?. <i>Blood</i> , 2006, 107, 3409-3410.	0.6	4
36	Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians. <i>BMC Infectious Diseases</i> , 2017, 17, 734.	1.3	4

#	ARTICLE	IF	CITATIONS
37	The prevalence of bright liver echo pattern in patients with chronic hepatitis C: correlation with steatosis and fibrosis. <i>Journal of Ultrasound</i> , 2016, 19, 91-98.	0.7	3
38	Bone mass preservation with high-dose cholecalciferol and dietary calcium in HIV patients following antiretroviral therapy. Is it possible?. <i>HIV Clinical Trials</i> , 2018, 19, 188-196.	2.0	3
39	HepaDisk â€œ A new quality of life questionnaire for HCV patients. <i>Digestive and Liver Disease</i> , 2019, 51, 1008-1015.	0.4	3
40	COVID-19: Considerations about immune suppression and biologicals at the time of SARS-CoV-2 pandemic. <i>World Journal of Clinical Cases</i> , 2021, 9, 5352-5357.	0.3	3
41	Safety and Efficacy of Direct-Acting Antivirals in Transfusion-Dependent Thalassemic Patients with Chronic Hepatitis C. <i>Hepatitis Monthly</i> , 2018, 18, .	0.1	3
42	A Protective HLA Extended Haplotype Outweighs the Major COVID-19 Risk Factor Inherited From Neanderthals in the Sardinian Population. <i>Frontiers in Immunology</i> , 2022, 13, 891147.	2.2	3
43	Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment. <i>Journal of Immigrant and Minority Health</i> , 2017, 19, 876-882.	0.8	2
44	Impact of direct-acting antiviral drugs for chronic hepatitis C on mood: Preliminary results from a longitudinal study. <i>General Hospital Psychiatry</i> , 2019, 56, 50-51.	1.2	2
45	Can Antiretroviral Therapy Modify the Clinical Course of HDV Infection in HIV-Positive Patients?. <i>Antiviral Therapy</i> , 2015, 20, 671-679.	0.6	1
46	F-7 Insulin resistance does not affect sustained virologic response in patients with chronic hepatitis C without cirrhosis treated with peg-interferon alfa 2a and ribavirin. <i>Digestive and Liver Disease</i> , 2011, 43, S94.	0.4	0
47	F-51 Virological response and HBV-DNA reduction during therapy with peginterferon alpha-2a (PEG-IFNÎ±-2a) in patients affected by HBeAg-negative chronic hepatitis B. <i>Digestive and Liver Disease</i> , 2012, 44, S48.	0.4	0
48	P-387 - Psychopatological symptoms and quality of life in patients receiving interferon: Results of a prospective study. <i>European Psychiatry</i> , 2012, 27, 1.	0.1	0
49	Association of IFNL4 genotype and ALT decrease is a new tool to predict viral eradication in HCV Sardinian patients with chronic hepatitis C, genotype 4, treated with PEG-IFNÎ± and Ribavirin. <i>Digestive and Liver Disease</i> , 2014, 46, e48-e49.	0.4	0
50	Oral bacterial load in autoimmune liver diseases: possible role or coincidence?. <i>Digestive and Liver Disease</i> , 2015, 47, e65.	0.4	0
51	Role of Killer cell immunoglobulin-like receptors and their HLA class I ligands in autoimmune hepatitis. <i>Digestive and Liver Disease</i> , 2015, 47, e29.	0.4	0
52	Transient elastography in patients with chronic autoimmune hepatitis: is a good tool in evaluation of hepatic fibrosis?. <i>Digestive and Liver Disease</i> , 2015, 47, e64.	0.4	0
53	Covid-19 vaccines work but other factors play a relevant role: a data analysis on spread and mortality in 24 countries. <i>Journal of Public Health Research</i> , 2022, 11, .	0.5	0
54	Verifying the Theory of Climate Affecting Lethality of COVID-19 by an Analysis in Two Climatic Zones of Chile. <i>Open Public Health Journal</i> , 2022, 15, .	0.1	0